This study investigates the prognostic significance of ARPC1A in low-grade glioma (LGG) progression. Using bioinformatics and experimental approaches, the researchers analyzed the expression of mitochondrial-related genes, including ARPC1A, in LGG patients. They found that ARPC1A is significantly associated with poor prognosis in LGG, with higher expression correlating with increased tumor proliferation and reduced apoptosis. ARPC1A was validated through nomogram analysis, which demonstrated its potential as an independent prognostic factor. Gene set enrichment analysis revealed that ARPC1A is involved in cancer-promoting pathways, including MAPK signaling. Experimental studies, including transfection assays, CCK-8 assays, and flow cytometry, confirmed that ARPC1A promotes LGG cell proliferation and inhibits apoptosis. Western blotting analysis showed that ARPC1A modulates MAPK signaling, suggesting its role in tumor progression. The study highlights ARPC1A as a promising biomarker for LGG prognosis and suggests its potential as a therapeutic target. Further research is needed to explore its clinical implications.This study investigates the prognostic significance of ARPC1A in low-grade glioma (LGG) progression. Using bioinformatics and experimental approaches, the researchers analyzed the expression of mitochondrial-related genes, including ARPC1A, in LGG patients. They found that ARPC1A is significantly associated with poor prognosis in LGG, with higher expression correlating with increased tumor proliferation and reduced apoptosis. ARPC1A was validated through nomogram analysis, which demonstrated its potential as an independent prognostic factor. Gene set enrichment analysis revealed that ARPC1A is involved in cancer-promoting pathways, including MAPK signaling. Experimental studies, including transfection assays, CCK-8 assays, and flow cytometry, confirmed that ARPC1A promotes LGG cell proliferation and inhibits apoptosis. Western blotting analysis showed that ARPC1A modulates MAPK signaling, suggesting its role in tumor progression. The study highlights ARPC1A as a promising biomarker for LGG prognosis and suggests its potential as a therapeutic target. Further research is needed to explore its clinical implications.